Form 4: Nuvation Bio CRO Executes Stock Option Exercise and Sale

Chief Regulatory Officer Kerry Wentworth exercised options for 36,750 shares and subsequently sold them under a 10b5-1 plan.

Summary

• Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc., exercised stock options for 36,750 shares at a strike price of $2.93.
• Following the exercise, the reporting person sold the 36,750 shares at a weighted-average price of $5.0144 per share.
• The transactions were executed pursuant to a pre-established Rule 10b5-1 trading plan dated December 4, 2025.
• Post-transaction, the reporting person retains direct ownership of 53,000 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents routine personal financial management by an executive.

Positives

• The transaction was conducted under a pre-arranged 10b5-1 plan, which typically indicates the sale is for personal financial planning rather than a reaction to non-public information.
• The exercise of options demonstrates the executive's participation in the company's equity incentive programs.

Negatives

• The transaction results in a reduction of the executive's direct equity stake in the company from 89,750 shares to 53,000 shares.

Risks

• Future sales by insiders may occur as part of the ongoing 10b5-1 plan, which could influence market sentiment regarding the stock.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The filing notes that the shares were sold at prices ranging from $5.00 to $5.05.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice in the biotechnology sector, allowing executives to diversify their holdings while maintaining compliance with SEC regulations.

Comparison to Industry Standards

• The use of a 10b5-1 plan is consistent with best practices for corporate governance among publicly traded biotech firms.
• The volume of shares sold is relatively small compared to the total outstanding shares of Nuvation Bio, suggesting minimal impact on corporate control.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed through a pre-planned mechanism.

Next Steps

• Continued monitoring of future Form 4 filings for additional insider activity.

Key Dates

Keywords

Nuvation Bio, NUVB, Insider Trading, Form 4, Stock Option Exercise, 10b5-1 Plan, Biotech